10 March, 2016
Skadden and Shearman & Sterling Advises On Sinco Pharmaceuticals’ Hong Kong IPO.
Shearman & Sterling advised Sinco Pharmaceuticals Holdings Limited (Sinco Pharmaceuticals) on its global offering and initial public offering (IPO) on the Main Board of The Stock Exchange of Hong Kong Limited. Skadden advised China Merchants Securities (HK) Co., Limited, the sole sponsor, sole global coordinator, sole bookrunner and sole lead manager.
The IPO was valued at HK$320 million (approximately US$41 million) on the Hong Kong Stock Exchange. Trade in the shares commenced on 10 March.
Sinco Pharmaceuticals is the third largest provider of marketing, promotion and channel management services in the PRC pharmaceutical industry.
The team was led by Hong Kong partners Christopher Betts and Will Cai, with associates Anthony Pang, Qin Liu and Richard Chang, and trainee Andy Wang.
The Shearman & Sterling team was led by partners Alan Yeung and Paloma Wang (Hong Kong-Capital Markets), with support from associates Wanda Woo, Marshall Chu (Hong Kong-Capital Markets) and Yuanjing Chen (Shanghai-Capital Markets) and legal assistant Coty Lee (Hong Kong-Capital Markets).
